Vibrio cholerae non-O1 serogroup associated with cholera gravis genetically and physiologically resembles O1 E1 Tor cholera strains. 1994

R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
Center for Food Safety and Applied Nutrition, Food and Drug Administration, Washington, D.C. 20204.

Until recently, only Vibrio cholerae strains of the O1 serogroup have been associated with epidemic cholera. In December 1992, an outbreak of cholera gravis in Vellore, India, was attributed to a new serogroup of V. cholerae recently designated O139. Serogroup O139 cholera has since spread to 13 countries and has reached pandemic proportions. Serogroup O139 cholera evades immunity to O1 cholera and is not detected by the standard O1 antigen test. Understanding the origins of O139 cholera and determining the relatedness of O139 to O1 cholera are necessary to device strategies for detecting, reporting, and controlling this new pandemic. In order to determine the origins of this novel cholera serogroup, O139 was analyzed for virulence genes, for virulence proteins and their regulation, and for its genomic background. We found that O139 and O1 V. cholera strains of the E1 Tor biotype possess highly homologous virulence genes encoding cholera toxin and toxin-coregulated pili and that the regulation of virulence protein expression likewise was indistinguishable between O139 and O1. Pulsed-field gel electrophoresis (PFGE) revealed the restriction digest pattern of O139 strains to be closely related to that of O1 serogroup E1 Tor biotype cholera strains from the Indian subcontinent. However, PFGE showed minor differences among individual O139 cholera isolates, suggesting that O139 V. cholerae is evolving.

UI MeSH Term Description Entries
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D002772 Cholera Toxin An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells. Cholera Toxin A,Cholera Toxin B,Cholera Toxin Protomer A,Cholera Toxin Protomer B,Cholera Toxin Subunit A,Cholera Toxin Subunit B,Choleragen,Choleragenoid,Cholera Enterotoxin CT,Cholera Exotoxin,Cholera Toxin A Subunit,Cholera Toxin B Subunit,Procholeragenoid,Enterotoxin CT, Cholera,Exotoxin, Cholera,Toxin A, Cholera,Toxin B, Cholera,Toxin, Cholera
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D014734 Vibrio cholerae The etiologic agent of CHOLERA. Bacillus cholerae,Bacillus cholerae-asiaticae,Liquidivibrio cholerae,Microspira comma,Pacinia cholerae-asiaticae,Spirillum cholerae,Spirillum cholerae-asiaticae,Vibrio albensis,Vibrio cholera,Vibrio cholerae-asiaticae,Vibrio comma
D014774 Virulence The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS. Pathogenicity

Related Publications

R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
March 2020, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
January 2020, Scientific reports,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
August 1989, Journal of clinical microbiology,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
November 1995, FEMS microbiology letters,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
November 2006, Journal of clinical microbiology,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
January 1989, Microbiology and immunology,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
December 1989, Journal of clinical microbiology,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
June 1993, Communicable disease report. CDR weekly,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
January 2013, PLoS neglected tropical diseases,
R H Hall, and F M Khambaty, and M H Kothary, and S P Keasler, and B D Tall
June 2008, Emerging infectious diseases,
Copied contents to your clipboard!